<DOC>
	<DOCNO>NCT01017120</DOCNO>
	<brief_summary>The purpose study assess safety efficacy new foam formulation tazarotene subject acne vulgaris .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Tazarotene Foam , 0.1 % , Subjects With Common Facial Acne</brief_title>
	<detailed_description>A multicenter , randomize , double-blind , vehicle-controlled , parallel-group study compare tazarotene foam vehicle foam subject acne vulgaris . Approximately 742 subject enrol randomize 1 2 study product group 1:1 ratio ( tazarotene foam : vehicle foam ) . Subjects apply tazarotene foam vehicle foam entire face daily 12 week ; study visit occur baseline ( week 0/day 1 ) week 2 , 4 , 8 , 12 .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Male female age 12 45 year , inclusive , good general health . An ISGA score 3 great baseline . Lesion count meeting follow criterion : 1 . Between 25 50 facial inflammatory lesion 1 facial nodular lesion ( &lt; 5mm ) , NO cystic lesion . 2 . Between 30 125 facial noninflammatory lesion , exclude nasal lesion . Regular menstrual cycle prior study entry female childbearing potential . Negative urine pregnancy test female childbearing potential . â€¢ Sexually active female childbearing potential participating study must agree use medically acceptable method contraception receive protocolassigned product . A woman childbearing potential define one biologically capable become pregnant ; include perimenopausal woman le 2 year last menses . Women currently sexually active must agree use medically accept method contraception become sexually active participate study . Male subject and/or partner must use medically acceptable form contraception . Capable understanding willing provide sign dated write voluntary informed consent protocol specific procedure perform . Ability willingness follow study procedure , attend schedule visit , successfully complete study . Female pregnant , try become pregnant , breast feeding . Use topical antibiotic face within past 2 week . Use systemic antibiotic acne treatment within past 4 week . Concurrent use medication know photosensitizers ( eg , thiazide , tetracycline ) possibility augment photosensitivity . Use topical corticosteroid face within past 2 week systemic corticosteroid within past 4 week . Use systemic retinoids ( eg , isotretinoin ) within past 6 month . Treatment estrogens , androgen , antiandrogenic agent 12 week less immediately prior study enrollment . Subjects treat medication 12 consecutive week prior study enrollment allow enroll long expect change dose drug , discontinue use study indicate treatment acne vulgaris . Use topical antiacne medication ( eg , benzoyl peroxide , retinoids , salicylate ) within past 2 week . Concomitant use facial product : abradant , facial , peel contain glycolic acid , mask , wash soap . Concomitant use medication report exacerbate acne ( eg , megadoses certain vitamin , haloperidol , immunosuppressant cyclosporine ) may impact efficacy assessment . Multivitamins , iron supplement , folate acceptable . Facial procedure ( eg , blue light , chemical laser peel , microdermabrasion ) within past 4 week . Require desire excessive prolonged exposure ultraviolet light study . Known hypersensitivity previous allergic reaction active component study product . A significant medical history currently immunocompromised . Use investigational product within past 4 week currently participate another clinical study . Any condition , judgment investigator , would put subject unacceptable risk participation study . Any major illness within 30 day study enrollment . Currently live household currently enrol subject ; employee Stiefel , investigator , CRO involve study ; immediate family member ( eg , partner , offspring , parent ) employee involve study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acne</keyword>
</DOC>